The world of corporate VCs is complex and rapidly evolving, with top decision-makers from multi-billion-dollar strategics continuously evaluating how they invest and align their efforts with medtech M&As and business development. During the LSI USA ’24 panel, titled Corporate VCs: What They Want, and How They Align With M&A and Business Development, industry leaders from Medtronic, Boston Scientific, Intuitive Ventures, Dexcom Ventures, and Orchestra BioMed shared valuable insights into their investment strategies and how they align with broader corporate goals.